Startup · $8.2m raised
Stevenage
Every investor coverage indicates participated in a round Myricx Pharma raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Seed | - |
| Brandon Capital Partners | Seed | - |
| Medical Research Commercialisation Fund (MRCF) | Seed | - |
| Sofinnova Partners | Seed | - |
Investors whose own portfolio pages list Myricx Pharma, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Myricx Pharma acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Andrew Bell | Chemistry Consultant · Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Dr Roberto Solari | Chief Executive (former) · Founder | Brandon BioCatalyst portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Mon 16 Nov 2020), Brandon BioCatalyst portfolio (Mon 16 Nov 2020) |
| Dr Robin Carr | Chief Development Officer | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Prof Ed Tate | Chief Scientific Officer · Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Myricx Pharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio